1st Quarter - Report — COHERUS BIOSCIENCES for COHERUS BIOSCIENCES, INC. (2024)

Firm

COHERUS BIOSCIENCES

Client

COHERUS BIOSCIENCES, INC.

Income

—

Expenses

$87,500

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Domestic Manufacturing Medicare implications on biosimilars, Part D reform Drug Rebate Reform Appropriations pertaining to American Made preference HHS Supply Chain Readiness HHS Biosimilar Uptake American-Made, Security of the American Pharmaceutical and Medical Supply Chain 117 - S.2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S.3311 - American Made Pharmaceuticals Act of 2023 FDA foreign inspections ASPR/BARDA funding and policy Interchangeability of biosimilars legislation

Lobbyist	Covered position, as disclosed
BEN KENNEY	Director of Strategic Communications and External Affairs, Centers for Medicare and Medicaid Services (2018-2021), Associate Administrator, General Services Administration (2017-2018), Legislative Aide, U.S. Sen. Daniel R. Coats (2011-2012)
ALI MCBRIDE	—
DAVID SANDERS	Legislative Affairs, Dept of Commerce, US Patent and Trademark Office (2005-2007) Legislative Assistant, Representative Marsha Blackburn (2002-2004) Legislative and Press Intern, Senator Fred Thompson (2000)

Contacted: Natl Security Council (NSC); White House Office; SENATE; Executive Office of the President (EOP); Defense, Dept of (DOD); Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Office of Science & Technology Policy (OSTP)

Bills named: S. 3311 (118th), S. 2082 (118th)

Government Issues GOV

Implementation of Buy American and Supply Chain Executive Orders American-Made Policies American-Made Supply Chain Security of the American Pharmaceutical and Medical Supply Chain Biosimilars Policy BARDA funding ASPR funding ARPA-H funding and implementation Industrial Supply and Financing IRA implementation Part D biosimilars utilization

Lobbyist	Covered position, as disclosed
BEN KENNEY	CMS, HHS
ALI MCBRIDE	—
DAVID SANDERS	—

Contacted: Health & Human Services, Dept of (HHS); White House Office; SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Executive Office of the President (EOP); Centers For Medicare and Medicaid Services (CMS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.